Literature DB >> 32949810

The Added Burden of Allergen Sensitization Among Children with Severe or Poorly Controlled Asthma.

W Gerald Teague1, Ahmar Iqbal2, Yao Ding3, Bradley E Chipps4, James L Zazzali5.   

Abstract

BACKGROUND: Allergen sensitization (AS) may negatively affect asthma outcomes in children with severe or poorly controlled (SPC) asthma.
OBJECTIVES: To examine the impact of AS on asthma exacerbations, health care use, and costs among children with SPC asthma in private and public insurance settings.
METHODS: This retrospective study analyzed children with SPC asthma aged 6 to 11 years from the MarketScan Commercial (private insurance) and Medicaid databases. Selection of children with SPC asthma was based on medical claims and asthma medication prescription claims. AS status was based on diagnoses of extrinsic asthma and allergic conditions. Children were followed for at least 12 months. Outcomes included asthma exacerbations, days with oral corticosteroids (OCS), and asthma-related health care use and costs. Adjusted generalized linear models were fit to compare outcomes in children with versus those without AS.
RESULTS: Among children with SPC asthma, 34% had AS (private insurance: N = 11,448; Medicaid: N = 10,800), 20% did not have AS (private insurance: N = 7744; Medicaid: N = 6535), and, in the remainder, AS status could not be determined. Claims data were available for ≥3 years on average. Children with AS had significantly higher adjusted rates of asthma exacerbations during follow-up than children without AS, and significantly more days with OCS use. Rates of asthma-related hospitalizations, emergency department visits, and health care costs were significantly higher among children with AS than among children without AS.
CONCLUSIONS: Children with SPC asthma and AS have relatively greater asthma-related health care use and costs compared with children with SPC asthma without AS.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allergen sensitization; Asthma; Claims; Health care costs; Health care utilization; Pediatric

Year:  2020        PMID: 32949810     DOI: 10.1016/j.jaip.2020.08.063

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  3 in total

1.  Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital.

Authors:  Hongwen Li; Qing Zhang; Jingru Wang; Shengnan Gao; Chunxiao Li; Jianxin Wang; Shuhua Zhang; Jiangtao Lin
Journal:  World Allergy Organ J       Date:  2021-09-21       Impact factor: 4.084

Review 2.  Asthma and Allergy: Unravelling a Tangled Relationship with a Focus on New Biomarkers and Treatment.

Authors:  Pablo Rodriguez Del Rio; Andrew H Liu; Magnus P Borres; Eva Södergren; Fabio Iachetti; Thomas B Casale
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

Review 3.  A Pragmatic Primary Practice Approach to Using Specific IgE in Allergy Testing in Asthma Diagnosis, Management, and Referral.

Authors:  Pascal Demoly; Andrew H Liu; Pablo Rodriguez Del Rio; Soren Pedersen; Thomas B Casale; David Price
Journal:  J Asthma Allergy       Date:  2022-08-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.